Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer

BACKGROUND: Trifluridine/tipiracil (TFTD), with or without bevacizumab (Bev), and regorafenib are salvage chemotherapy options for metastatic colorectal cancer (mCRC). Here, we examined the influence of precedent drug on the efficacy of subsequent drug. METHOD: The subjects were patients with mCRC w...

Descripción completa

Detalles Bibliográficos
Autores principales: Oshima, Kotoe, Hirano, Hidekazu, Shoji, Hirokazu, Iwasa, Satoru, Okita, Natsuko, Takashima, Atsuo, Boku, Narikazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9162345/
https://www.ncbi.nlm.nih.gov/pubmed/35653412
http://dx.doi.org/10.1371/journal.pone.0269115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9162345/
https://www.ncbi.nlm.nih.gov/pubmed/35653412
http://dx.doi.org/10.1371/journal.pone.0269115

Ejemplares similares